Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma

Cancer Research

Volumn 66, Issue 19, 2006, Pages 9771-9780

  Wang, Sophia S ^a   Cerhan, James R ^b,c   Hartge, Patricia ^a   Davis, Scott ^d   Cozen, Wendy ^e   Severson, Richard K ^f   Chatterjee, Nilanjan ^a   Yeager, Meredith ^a   Chanock, Stephen J ^a   Rothman, Nathaniel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MALE; NONHODGKIN LYMPHOMA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; FALSE POSITIVE REACTIONS; FEMALE; GENES, MHC CLASS II; GENOTYPE; HAPLOTYPES; HUMANS; INFLAMMATION; LYMPHOMA, NON-HODGKIN; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; SEER PROGRAM; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 33750365510     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0324     Document Type: Article

References (58)

1. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
2. Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol 2002;29:258-63.
3. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994;86:1600-8.
4. Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Precv 2004;13:1415-21.
5. Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005;97:1466-74.
6. Monne M, Piras G, Palmas A, et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin lymphoma. Am J Hematol 2004;76:14-8.
7. Mainou-Fowler T, Dickinson AM, Taylor PR, et al. Tumour necrosis factor gene polymorphisms in lymphoproliferative disease. Leuk Lymphoma 2000;38:547-52.
8. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002;100:3037-40.
9. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin lymphoma outcome. Blood 1998;91:3574-81.
10. Gibson AW, Edberg JC, Wu J, et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915-22.
11. Hajeer AH, Hutchinson IV. TNF-α gene polymorphism: clinical and biological implications. Microsc Res Tech 2000;50:216-28.
12. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
13. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-32.
14. Picard C, Casanova JL. Inherited disorders of cytokines. Curr Opin Pediatr 2004;16:648-58.
15. Keen LJ. The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol 2002;10:143-6.
16. Germain RN. An innately interesting decade of research in immunology. Nat Med 2004;10:1307-20.
17. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 2004; 63:S84-9.
18. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004;36:565-74.
19. Bhatti P, Sigurdson AJ, Wang SS, et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 2005;14:2449-53.
20. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
21. Garcia-Closas M, Egan KM, Abruzzo J, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001;10:687-96.
22. Rothman N. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph consortium. Lancet Oncology 2006;7:27-38.
23. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:528-32.
24. Benjamini Y HY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc Ser B Methodol 1995;57:289-300.
25. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
27. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNFα, LTα, and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000;1:185-90.
28. Belfer I, Buzas B, Hipp H, et al. Haplotype structure of inflammatory cytokines genes (IL1B, IL6, and TNF/LTA) in US Caucasians and African Americans. Genes Immun 2004;5:505-12.
29. Escoffier S. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
30. R Development Core Team. R: A language and environment for statistical computing. Vienna (Austria): Foundation for Statistical Computing; 2004.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
32. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004; 5:315-29.
33. Chouchane E, Ahmed SB, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factor-α promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997;80:1489-96.
34. Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol 1999;107:388-91.
35. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-9.
36. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991;173:209-19.
37. Coussens EM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
38. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 2004;306:966-8.
39. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature 2003; 422:835-47.
40. Friedland JS. Chemokines and human infection. Clin Sci (Lond) 1995;88:393-400.
41. Savage SA, Abnet CC, Mark SD, et al. Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:2251-7.
42. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. Blood 1999;94:4220-32.
43. Karassa FB, Trikalinos TA, Ioannidis JP. The role of Fcγ RIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother 2004;58:286-91.
44. Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002;46:1563-71.
45. Salmon JE, Millard S, Schachter LA, et al. Fc γ RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
46. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-34.
47. Nelson GW, Martin MP, Gladman D, et al. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004;173:4273-6.
48. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003;349:996-8.
49. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol 2003;109:37-45.
50. Mitsuyasu H, Izuhara K, Mao XQ, et al. Ile50Val variant of IL4Rα upregulates IgE synthesis and associates with atopic asthma. Nat Genet 1998;19:119-20.
51. Park CS, Yoon SO, Armitage RJ, Choi YS. Follicular dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form. J Immunol 2004;173:6676-83.
52. Skinnider BF, Kapp U, Mak TW. The rote of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002;43:1203-10.
53. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
54. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-8.
55. Marchini J, Cardon LR, Phillips MS, Donnelly P. The effects of human population structure on large genetic association studies. Nat Genet 2004;36:512-7.
56. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
57. Bjorck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome of patients with follicular lymphoma. Blood 2005;105:2908-15.
58. Magrath I. Molecular characteristics of diffuse large-B-cell lymphoma. N Engl J Med 2002;:346:1998-9.